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Abstract 
 
The tumor-promoting functions of Ataxia-telangiectasia  
mutated (ATM) in cancer cells 
 
Wei-Ta Chen, M.A. 
The University of Texas at Austin, 2015 
 
Supervisor:  Kyle Miller 
 
 Ataxia-telangiectasia mutated (ATM) protein kinase regulates the DNA damage 
response (DDR) and is associated with cancer suppression by protecting cells from DNA 
double-strand breaks (DSBs). However, how ATM functions outside of DSB signaling is 
less clearly understood. Here, we report a new cancer-promoting role for ATM in 
stimulating cell migration and invasion independently of DSB signaling or induction. We 
used two highly metastatic human breast cancer cell lines to corroborate that ATM is 
required for cell migration and invasion. Microarray analysis of cells depleted for ATM 
identified interleukin-8 (IL-8) as a target since the exogenous addition of IL-8 rescued 
migration and invasion defects in ATM-deficient cells. Finally, ATM depletion in human 
cancer cells reduced lung metastasis in a mouse xenograft model. These findings shed 
light on tumor-promoting functions of ATM. Therefore, in addition to its canonical roles 
in tumor suppression, ATM promotes tumor progression as well. 
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Chapter 1 Introduction 
 
1.1 DNA damage and cancer therapy 
Cancer is an evolutional disease that requires multistep processes to occur before full 
malignant transformation can take place. The hallmarks of cancer include sustaining 
proliferative signaling, activating invasion and metastasis, and so on (Hanahan and 
Weinberg, 2011). The underlying cause of these hallmarks is genomic instability, which 
is one of the most pervasive characteristics of most human tumors (Hanahan and 
Weinberg, 2011). Currently, other than surgery, radiation and chemotherapy are the two 
major treatments for cancer (Cheung-Ong et al., 2013; Lord and Ashworth, 2012). Both 
of these treatments exploit the enhanced sensitivity of cancer cells to DNA damage as 
replication of damaged DNA increases cell death (Cheung-Ong et al., 2013; Lord and 
Ashworth, 2012). Of all types of DNA damage, DNA double-strand breaks (DSBs) 
represent the most toxic and challenging to cells. If unrepaired or repaired inaccurately, 
DSBs result in chromosomal discontinuities and lead to genome instability. Most of 
DNA-damaging agents exploit the genotoxic nature of DSBs to eliminate cancer cells in 
the clinic (Cheung-Ong et al., 2013; Lord and Ashworth, 2012). In addition, it has been 
shown that a topoisomerase-1 inhibitor, camptothecin, impairs cell motility (Cohen et al., 
2008). However the extensive investigation of the effects of DNA-damaging agents on 
cell motility remains lacking. Elucidation of the effects of anti-cancer treatments on 
motility of cancer cells can provide new insights into cancer therapy. 
 
 2 
1.2 DNA damage response and Ataxia-telangiectasia mutated 
DNA damage is a continuous threat to genetic material of cells. These damage result 
from either endogenous sources such as replication errors and base deamination or 
exogenous agents including ultraviolet light from sunlight, radiation, and DNA-damaging 
agents used in cancer chemotherapy (Ciccia and Elledge, 2010). The protection of our 
genome is crucial for preventing human diseases including cancers (Jackson and Bartek, 
2009). To counteract DNA damage and preserve genomic integrity, cells have evolved a 
complex network of diverse cellular responses, termed the DNA damage response 
(DDR), which senses damaged DNA, transduces signals and promotes DNA repair 
(Ciccia and Elledge, 2010; Jackson and Bartek, 2009). The protein kinase Ataxia-
telangiectasia mutated (ATM) is one of the important components of DDR, especially for 
DNA double-strand breaks (DSBs) repair. In response to DSBs, ATM is activated in a 
MRE11-RAD50-NBS1 (MRN) complex-dependent manner (Lee and Paull, 2005) and 
underdoes auto-phosphorylation and dimer dissociation(Bakkenist and Kastan, 2003). 
Recently, it has been shown that oxidative stress activates ATM in the absence of DSBs 
(Guo et al., 2010). Activated ATM phosphorylates targets, including CHK2 and p53, to 
trigger its downstream cellular responses, such as apoptosis, cell-cycle arrest and 
senescence (Lavin, 2008; McKinnon, 2012), which serve as anti-cancer barrier to 
suppress the growth of tumor cells. These functions of ATM in the DDR highlight the 
importance of its roles in repairing DNA damage and preserving genome integrity, 
thereby preventing tumor formation. 
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1.3 ATM-CHK2-p53 pathways in precancerous lesions and cancers 
The constitutively activated ATM-CHK2-p53 cascades have been observed in 
premalignant human tumors, and several lines of evidence support that the active 
signaling pathways emerge as a barrier for tumorigenesis in the early stages of cancer 
development (Bartkova et al., 2005; Bartkova et al., 2006; Di Micco et al., 2006; 
Gorgoulis et al., 2005; Halazonetis et al., 2008). These studies suggest that senescence 
and apoptosis induced by these pathways are major mechanisms to constrain tumor 
progression. ATM-CHK2-p53 signaling pathways, however, play a role not only in 
precancerous regions but also in cancers untreated by radiation or chemotherapy 
(Bartkova et al., 2005; DiTullio et al., 2002), suggesting ATM may have functions 
independent from exogenous DNA damage. In addition, cancer cells often exhibit 
genomic instability and endogenous oxidative stress to drive malignant transformation 
(Hills and Diffley, 2014; Klaunig et al., 2010). DDR factors are often compromised in 
cancer cells, thus affecting DNA damage-based therapy both positively and negatively 
(Bouwman and Jonkers, 2012). This raises an interesting question of whether ATM, an 
upstream factor in DDR and activated in cancer cells without exogenous DNA damage, is 
involved in the malignancy of cancers. Indeed, ATM has been shown to be required for 
pathological neoangiogenesis (Okuno et al., 2012), which is one of the hallmarks of 
cancer. A recent study has shown that ATM is required for the formation of acute 
myeloid leukemia as ATM is critical for maintaining the differentiation blockade and 
thereby promotes the growth of MLL-AF9 leukemic cells (Santos et al., 2014a). 
However, whether ATM is involved in cell migration and invasion remains unknown. 
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The elucidation of whether ATM plays a role in cell motility of cancers will shed light on 
the novel oncogenic functions of ATM.  
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Chapter 2 Materials and methods 
2.1 Cell culture, reagents and treatments 
Dulbecco's Modified Eagle's Medium (DMEM) and RPMI-1640 medium were used to 
culture MDA-MB-231 and BT-549 breast cancer cells, respectively. DNA-damaging 
treatments used in wound-healing assay were as follows: doxorubicin (Dox, 100 nM), 
phleomycin (Phleo, 90 μg/ml), etoposide (Et, 40 µM), and ionizing radiation (IR, 20 Gy) 
by a Faxitron X-ray unit. Cells were incubated with these agents for 48 h except IR, 
which is imposed on cells at 0 h followed by incubating the cells with regular medium. 
 
2.2 Western blotting, ChIP and subcellular fraction 
For whole cellular lysate, cells were washed once with PBS, and lysed in Laemmli buffer 
(4% SDS, 20% glycerol and 120 mM Tris, pH 6.8). The cell lysates were sonicated and 
boiled for 5 min at 95°C followed by centrifugation before loading. Samples were 
separated by SDS-PAGE and detected using standard chemiluminescence (GE 
Healthcare Amersham ECL prime) using a Bio-Rad Molecular Imager® ChemiDoc™ 
XRS+ system. For chromatin immunoprecipitation, cells were crosslinked in 1% 
formaldehyde for 10 min at room temperature followed by 125 mM glycine treatment to 
stop the reaction. Cells were then lysed in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 
mM NaCl, 2 mM EDTA, pH 8.0, 1% NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS and 
a proteinase inhibitor) and sonicated. Samples were immunoprecipitatd with NF-κB p65 
antibody overnight at 4°C. After incubation of protein A agarose for 4 h at 4°C, beads 
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were washed once with the following solutions: TSE-150 (1% Triton X-100, 0.1% SDS, 
2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl), TSE-500 (1% Triton X-100, 
0.1% SDS, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 500 mM NaCl), LiCl buffer (0.25 M 
LiCl, 1% NP-40, 1% SOC, 1 mM EDTA, 10 mM Tris, pH 8.0), and TE buffer (10 mM 
Tris pH 8.0, 0.1 mM EDTA pH 8.0). After reverse crosslinking, DNA was purified using 
a PCR purification kit. qRT-PCR analysis was performed using SYBR green (Applied 
Biosystems) on an Applied Biosystems StepOne Plus system. For cytoplasmic and 
nuclear extract, 3x106 cells were suspended in 150 µl solution containing 10mM HEPES, 
pH7.9, 10mM KCl, 1.5mM MgCl2, 0.34M sucrose, 10% glycerol, 1mM DTT, 0.1% 
TritonX-100 and a proteinase inhibitor. Followed by incubating on ice for 5 min, cells 
were harvested by centrifugation at 1,300g for 4 min to acquire cytoplasmic (supernatant) 
and nuclear (pellet) fractions. Then the pellet was added 200 µL of Laemmli buffer and 
sonicated for 10 min. These extracts were analyzed as above described. Antibodies used 
for western blotting were as follows: H2AX (Cell Signaling, #2595), γH2AX (Novus 
Biologicals, #NB100-384), Phospho-p53 (Ser15) (Cell Signaling, #9284), p53 (Active 
Motif, #39553), ATM (Santa Cruz Biotechnology, #sc-135663), CHK2 (Cell Signaling, 
#2662), KAP1 (Santa Cruz Biotechnology,#sc-33186), phosphor-KAP1 Ser824 (Bethyl 
Laboratories, # A100-767A), MRE11 (Abcam, #ab214), NBS1 (Novus Biologicals, 
#NB100-143), NF-κB p65 (Santa Cruz Biotechnology, #sc-109), and β-tubulin (Abcam, 
#ab6046). Secondary antibodies conjugated to horseradish peroxidase (Cell Signaling) 
were used for enhanced chemiluminescence. 
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2.3 siRNA transfection 
Small interfering RNA (siRNA) SMARTpools were obtained from Dharmacon: siNC 
(Non-targeting pool), siATM, siCHK2, siMRE11, siNBS1 and sip53. The sequences for 
independent siATM-1 and siATM-2, which are part of siATM SMARTpools, are 
GCAAAGCCCUAGUAACAUA and GGGCAUUACGGGUGUUGAA (Dharmacon). 
The sequence for siIL-8 is GCCAAGGAGUGCUAAAGAA (Dharmacon). The sequence 
for sip65 is GAUCAAUGGCUACACAGGAUU (Dai et al., 2005). Lipofectamine 
RNAiMAX (Invitrogen) was used to transfect the indicated siRNA into cells following 
the manufacturer’s instructions. 
 
2.4 Luciferase reporter assay 
The promoter region of IL-8 corresponding to -1423/+96 bp was cloned from MDA-MB-
231 cells by PCR using 5’-CTCGAGGTAACCCAGGCATTATTTTA-3’ and 5’-
AGATCTAGCTTGTGTGCTCTGCTGTC-3’ primers. The PCR fragment was then 
subcloned into pCR-Blunt II-TOPO vector (Invitrogen). The IL-8 promoter was cut with 
XhoI and BglII and cloned into Xho1/BglII treated pNANOG-Luc (Addgene No. 25900). 
After sequencing, this IL-8 promoter driven luciferase construct was named as pIL8-Luc. 
As a negative control, we made another IL-8 reporter with mutated NF-κB binding 
(named as mut pIL8-Luc) by using pIL8-Luc as a template and the following primers:    
5’-ATGGGCCATCAGTTGCAAATCGTTAACTTTCCTCTGACATAATGAAAAGA-
3’ 
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5’-TCTTTTCATTATGTCAGAGGAAAGTTAACGATTTGCAACTGATGGCCCAT-
3’ 
The luciferase assay was performed by transfecting with indicated siRNA on day 1. After 
24 h, pIL8-Luc or mut pIL8-Luc and a trace amount of pRL-SV40P as an internal control 
(Addgene No. 27163) were transfected into cells with FugeneHD (Promega). On day 3 or 
4, cells were lysed and both firefly and renilla luciferase were measured by using Dual-
Glo Luciferase assay system (Promega) on a microplate reader (TECAN). All firefly 
luciferase measurements were corrected for renilla luciferase values. The ratios were 
normalized to control groups and expressed as relative luciferase unit (RLU). 
 
2.5 Wound-healing, soft agar and live-cell imaging 
MDA-MB-231 and BT-549 cells were seeded into 6-well plates and cultured to 
confluence. Cells were then wounded with sterile pipette tips and washed once with PBS. 
Then cells were treated or untreated with DNA-damaging agents as described. For 
wound-healing assay with siRNA treatments, cells were transfected with indicated 
siRNA and after 48 h, wounds were made as described above. Pictures were acquired at 0 
h and 48 h using an EVOS fluorescence microscope. Representative pictures were from 
three independent experiments and quantified by using TScratch software (Geback et al., 
2009). Soft agar assays were performed on shNC and shATM MDA-MB-231 cells 
essentially as described (Xhemalce et al., 2012). For live analysis of cell motility, MDA-
MB-231 cells were plated in glass round petri dish (TED PELLA, INC) and treated as 
indicated. Images were taken every 15 min using Olympus confocal microscope and 
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analyzed with ImageJ manual tracking plugin. Greater than 100 cells were analyzed for 
each experiment and sample and results provided are from three independent 
experiments. 
 
2.6 Flow cytometry 
For cell-cycle analysis, MDA-MB-231 cells untreated or treated with indicated DNA-
damaging agents for 48 h, except that cells were exposed to IR at 0 h, were trypsinized 
and fixed in 70% ice-cold ethanol overnight at 4°C. Cells were centrifuged, suspended 
and incubated in PBS containing propidium iodide (50 μg/ml) and RNase A (100 μg/ml) 
for 30 minutes at room temperature. DNA content was analyzed by using BD Accuri C6 
flow cytometer, and FlowJo software was used to analyze flow cytometry data. 
Intracellular reactive oxygen species (ROS) was determined by CM-H2DCFDA 
(Invitrogen). Briefly, following indicated treatments, cells were trypsinized and incubated 
with 5 μM CM-H2DCFDA in PBS for 30 min in the 37  °C incubator. Cells were then 
returned to phenol red-free medium for 15 min recovery period and immediately 
analyzed by BD Accuri C6 flow cytometer. 4 mM H2O2 treatment served as a positive 
control and 10mM N-acetyl-cysteine (NAC) was used as a reducing agent. Data were 
analyzed using FlowJo and mean fluorescence intensity was used as a measure of ROS. 
 
2.7 RTCA real-time analysis of proliferation, migration and invasion 
xCELLigence Real-Time Cell Analyzer (RTCA; Roche Diagnostics) was used to monitor 
cell proliferation, migration and invasion independently in a label-free, real-time setting. 
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When cells contact and adhere to electrical sensors, this leads to increasing electrical 
impedance. The impedance correlates with an increase in proliferating, migrating or 
invading cells, derived as a parameter called cell index. For proliferation experiments, 
cells were treated as indicated and seeded in quadruplicates on E-plate. For migration and 
invasion assays, following indicated treatments, cells were starved in serum-free medium 
overnight and seeded in quadruplicates on CIM-plate. Matrigel (BD Biosciences) was 
diluted in serum-free medium at a ratio of 1:40 and coated on CIM-plate only for 
invasion. Regular growth medium was added in the lower chamber as chemoattractant. 
The cell index was measured every 15 min, and the results were represented as 
normalized cell index. For exogenous addition of interleukin-8 (IL-8) (PEPROTECH), 
150 ng/ml of IL-8 was added to cells transfected with siATM and 200 ng/ml of IL-8 was 
added to cells depleted for p53. 
 
2.8 Microarray analysis 
Total RNA form cells transfected with siNC, siATM or sip53 was extracted using 
RNeasy Mini kit (Qiagen) following manufacturer’s instructions. All RNA was DNase 
treated before sending to Microarray core facility at DANA-Farber Cancer Institute to 
perform Affymetrix GeneChip Human Gene 2.0 ST array (n=2 in each group).  
Affymetrix Expression Console (EC) was used to generate CHP files from CEL files. 
Then CHP files were loaded into Affymetrix Transcriptome Analysis Concole (TAC) 
software. Normalizaton and gene expression analysis were performed in TAC software. 
Gene ontology analysis was analyzed using the “Functional Annotation Tool” in DAVID 
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(http://david.abcc.ncifcrf.gov/home.jsp) and biological process terms are shown (Huang 
da et al., 2009). 
 
2.9 Quantitative real-time PCR 
Total RNA from cells treated as indicated was purified using RNeasy Mini kit (Qiagen) 
and treated with DNase according to manufacturer’s instructions. 1 μg of total RNA was 
used for cDNA synthesis with SuperScript III first-strand synthesis system. To analyze 
IL-8 mRNA expression, we designed gene-specific qPCR primers: 5’-
AAGAAACCACCGGAAGGAAC-3’ and 5’-ACTCCTTGGCAAAACTGCAC-3’ for 
IL8. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (Quantitect primer assay, 
Qiagen) was used for normalization. To perform ChIP-qPCR, we used the following 
primers: 1) 5’-GTGTGATGACTCAGGTTTGC-3’ and 5’-
GTTTGTGCCTTATGGAGTGC for IL-8 promoter and 2) 5’-
CGGAAAGATCGCCATATATGGAC-3’ and 5’-ACCGGCAGAGAAACGCGA-3’ for 
actin promoter. Quantitative real-time PCR analysis was performed using SYBR green 
(Applied Biosystems) on an Applied Biosystems StepOne Plus system. 
 
2.10 Mouse lung metastasis and orthotopic tumor growth assay 
Stable MDA-MB-231 shNC and shATM cells were made by using shATM (sequence: 
GAAGTAGAAGGAACCAGTTACCATGAATC) and shNC (control) plasmids from 
Origene. These cells were maintained in regular DMEM with 0.2 μg/ml puromycin. 
Balb/c mice were maintained according to the University of Texas at Austin Institutional 
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Animal Care and Use Committee guidelines. 0.5 × 106 shNC or shATM MDA MB 231 
breast cancer cells were injected into the mouse tail vein. Mice were then monitored daily 
for symptoms of distress, including difficulty breathing, ruffled appearance, and limited 
mobility. Surviving mice were euthanized nine weeks after cell injections. Mouse lungs 
were perfused with India ink to quantify metastatic lesions as previously reported 
(Williams et al., 2004). For the orthotopic tumor experiment, 2 × 106 shATM or shNC 
MDA MB 231 cells were injected into the #4 mammary fat pad of six week-old Balb/c 
mice. Mice were palpated 3 times weekly until tumors reached 750 mm3. Tumor size was 
expressed as tumor volume (mm3) and calculated by the formula: volume = (smaller 
dimension2 x larger dimension)/2. 
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Chapter 3 Results 
3.1 Effects of DNA-damaging agents on cell motility 
Genomic instability is one of the most prevalent characteristics of human cancers 
(Hanahan and Weinberg, 2011). Rapid cell growth and mutated DNA repair and 
signaling pathways attributed to genomic instability make cancer cells more sensitive to 
DNA damage, especially to DSBs. A myriad of DNA-damaging drugs are DSB-inducing 
damaging agents that can introduce exogenous DNA damage to cancer cells, thereby 
increasing their cell death (Cheung-Ong et al., 2013; Lord and Ashworth, 2012). 
However, the effects of DNA-damaging agents on cell behavior, including motility of 
cancer cells, remain unclear. We used the highly aggressive, motile breast cancer cell line 
MDA-MB-231 to study cell motility. To evaluate the effects of different types of DNA-
damaging agents, including doxorubicin, phleomycin, etoposide, and ionizing radiation 
(IR) on cellular motility, we employed wound-healing assays on MDA-MB-231 cells 
treated with varied agents and observed their migration for 48 h. We found these agents 
only have little effects on cellular motility (Figures 1A-B) although these agents all 
caused cell-cycle arrest and growth inhibition (Figures 1C-D). These data suggest that 
cell migration is independent of DSBs, cell-cycle arrest and growth inhibition.  
 
3.2 ATM promotion of cell migration and invasion is independent of DSBs 
Defective DDR genes and DNA damage signaling influence DNA damage–based therapy 
positively and negatively (Bouwman and Jonkers, 2012). As ATM is an upstream factor 
in response to DNA damage and regulates many cellular responses, we tested its role in 
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cell migration. Surprisingly, we observed defects in cell migration in cells deficient for 
ATM in both the absence and presence of exogenous DNA damage (Figures 2A-B). 
Phosphorylated KAP1 and p53 expression was increased in the presence of IR and 
reduced when ATM was depleted, confirming both KAP1 and p53 are ATM targets 
(Figure 2B). Next, we used xCELLigence Real-time cell analyzer (RTCA) system to 
measure cell proliferation, migration and invasion in real-time. By using this system, we 
observed that knockdown of ATM had a strong inhibitory effect on the migration and 
invasion, but not proliferation, of the MDA-MB-231 cells (Figure 2C). Together, these 
results indicate that ATM promotes cell motility in the absence of exogenous DNA 
damage, a common situation before cancers are treated with chemotherapy, suggesting 
that ATM has tumor-promoting functions by promoting cell migration and invasion. 
 
3.3 Both ATM and p53 are require for cell migration and invasion 
ATM is activated by DNA double-strand breaks through MRE11-RAD50-NBS1 (MRN) 
complex (Lee and Paull, 2005), and activated ATM can phosphorylate its targets 
including CHK2 and p53 to initiate downstream cellular responses (Lavin, 2008; 
McKinnon, 2012). After establishing that ATM is required for migration and invasion in 
MDA-MB-231 cells in the absence of DNA damage, we further investigated whether 
other DDR factors, including MRE11, NBS1, and CHK2, are involved in cellular 
motility. MDA-MB-231 cells transfected with siMRE11, siNBS1 or siCHK2 did not 
exhibit reduced motility (Figures 3A-C), suggesting ATM-mediated motility is 
independent of DSB signaling. Since ATM is also activated by oxidative stress 
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independently of DSBs (Guo et al., 2010), we speculated that ATM-mediated motility 
could result from oxidative stress. Indeed, the addition of reducing agent N-
acetylcysteine (NAC) impaired cell migration (Figure 3D). We also confirmed that NAC 
reduced endogenous oxidative stress (Figure 3E). To rule out any effects of proliferation 
on cell migration, we performed live-cell imaging to track the migration of individual 
cells. We observed reduced total cell path and speed in NAC-treated cells compared with 
control cells. (Figures 3F-G). These data suggest that ATM promotes cell migration 
independent of DSB signaling. p53 is phosphorylated by ATM in response to oxidative 
stress (Guo et al., 2010) and mutant p53 is involved in migration and invasion in MDA-
MB-231 cells under TGF-β treatment (Adorno et al., 2009). We hypothesized that p53 
and ATM could act together to promote cell motility. As expected, when depleting p53, 
we observed a reduction in cell migration (Figures 4A-B). Interesting, co-depletion of 
ATM or p53 leads to similar reduced cell migration as single gene knockdown (Figures 
4A-B). By using xCELLigence system, we measure the invasion capability for cells 
deficient for ATM, p53 or both. Although mildly reduced proliferation was observed in 
p53-depleted cells, co-depletion of ATM and p53 exhibited a similar reduction in cell 
migration and invasion (Figures 4C), suggesting ATM and p53 are epistatic. In addition, 
live-cell imaging revealed reduced speed and total migration in ATM- or p53-codepleted 
cells (Figures 4D-E). Thus these results rule out proliferation effects on cell motility and 
confirm that ATM and p53 are required for cell migration and invasion. In order to see 
whether ATM- and p53- mediated motility are general, we used another highly motile 
breast cancer cell line BT-549 that also contains mutant p53. In consistence with results 
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from MDA-MB-231 cells, depletion of ATM led to a 60% reduction in cell migration 
(Figure 5A). Co-depletion of ATM and p53 again showed similar reduction in cell 
migration as single gene knockdown (Figure 5B). Taken together, these results by using 
two different cell lines suggest that ATM and p53 promote cell migration and invasion in 
highly motile cancer cells.  
 
3.4 Interleukin-8 (IL-8) is regulated by ATM 
To identify the potential targets accounting for the reduced motility in cells deficient for 
ATM or p53, we performed microarray analysis in MDA-MB-231 cells transfected with 
siATM, sip53 or control siRNA. According to the analysis, 216 and 514 genes were 
differentially expressed in cells depleted for p53 or ATM, respectively and 38 genes were 
concordantly up- or down-regulated in cells transfected with siATM or sip53 (Figure 
6A). Interestingly, interleukin-8 (IL-8) was found to be the most down-regulated gene in 
both siATM or sip53 treated cells (Figure 6A). Quantitative real-time PCR (qPCR) 
analysis validated that IL-8 expression was highly reduced in cells deficient for ATM or 
p53 in both MDA-MB-231 and BT-549 cell (Figures 6B-C). To further investigate 
whether ATM or p53 regulates IL-8 expression at transcriptional level, we cloned IL-8 
promoter from MDA-MB-231 cells and performed luciferase reporter assay. Consistent 
with a previous study (Freund et al., 2004), NF-κB binding site is crucial for efficient IL-
8 promoter activity as mutated NF-κB binding site (mut IL-8) lead to a ~90% reduction 
in IL-8 promoter activity (Figure 6D). Interestingly, the activity of IL-8 promoter was 
also abrogated in cells depleted for ATM or p53 as mut IL-8 (Figure 6D), showing that 
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ATM regulation of IL-8 occurs at transcriptional level. As expected, the depletion of NF-
κB p65, a subunit of NF-κB dimer, impaired IL-8 expression in MDA-MB-231 cells 
(Figure 6E). Both ATM and p53 are known to be required for NF-κB activation and 
localization in response to various stimuli (Hoesel and Schmid, 2013; Wuerzberger-Davis 
et al., 2007). To determine if loss of ATM or p53 affects p65 localization, we 
investigated the nuclear localization of p65 in MDA-MB-231 cell under normal situation. 
Nuclear localization of NF-κB p50/p65 dimer enables transcriptional activation of this 
complex, so we assessed the localization of p65 as a readout. Depletion of ATM or p53 
impaired p65 localization into nucleus, which is in line with the reduced IL-8 expression 
in cells deficient for ATM or p53 (Figure 6F). In consistence with this, chromatin 
immunoprecipitation (ChIP) of NF-κB p65 on IL-8 promoter revealed that loss of ATM 
or p53 abrogated p65 binding to IL-8 promoter (Figure 6G).  Taken together, these 
results strongly suggest that ATM and p53 are both required for NF-κB localization and 
its activity, which is necessary to regulate IL-8 expression. Further analyses supported the 
notion that IL-8 is the gene responsible for migration and invasion defects in MDA-MB-
231 cells as 1) IL-8 depletion led to reduced migration and invasion, 2) NAC treatment 
impaired IL-8 expression, 3) H2O2 addition increased IL-8 expression, and 4) H2O2-
induced IL-8 expression was dependent on ATM (Figures 7A-E). Thus, these results 
indicate that ATM promotion of IL-8 expression depends in endogenous oxidative stress 
through the regulation of NF-κB. 
 
 18 
3.5 ATM promotes tumor progression in vivo 
To determine whether IL-8 down-regulation is the underlying cause of impaired 
migration and invasion in cells depleted for ATM or p53, we performed rescue 
experiments by adding exogenous IL-8. The addition of IL-8 partially restored the 
migration and invasion in cells depleted for ATM or p53 (Figures 7F-G), suggesting 
ATM and p53 promotes motility partially through IL-8. ATM is considered a tumor 
suppressor since its depletion in mice results in tumors, and patients with mutations in 
ATM in the human disorder Ataxia telangiectasia are prone to cancer formation (Cremona 
and Behrens, 2014; Shiloh and Ziv, 2013; Stracker et al., 2013). However, our results 
above suggest that ATM through IL-8 to promote migration and invasion in vitro; this 
prompted us to assess whether ATM could affect tumor progression and promotes 
metastasis. MDA-MB-231 cells form lung tumors in immune-deficient mice. Therefore, 
we sought to address whether ATM could promote tumor growth using this xenograft 
model. We generated a MDA-MB-231 cell line with stable ATM depletion via shRNA. 
Both shATM and shNC cells formed colonies similarly in soft agar (Figures 8 A-B), 
suggesting loss of ATM does not affect cell transformation. Next, to examine the 
influence of ATM on tumor growth in vivo, we orthotopically injected these cells into 
mammary fat pad. We found that shATM-injected mice exhibited an increase in the 
primary tumor growth, which is consistent with the canonical role of ATM as a tumor 
suppressor (Figure 8C). To address whether loss of ATM could affect the ability of these 
cells to colonize secondary sites, we performed tail vein injections with shATM and 
shNC MDA-MB-231 cells and assessed lung colonization after 9 weeks. Remarkably, 
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lung tumor formation was highly reduced in mice with shATM compared to control cells 
(Figures 8D-E). To relate the findings in this study to clinical patient data, we examined 
the relationship between IL-8 expression and metastasis in human breast cancer. We 
analyzed a set of expression arrays from 560 breast cancer patients with clinical 
annotation (Morales et al., 2014). IL-8 expression was significantly associated with 
metastasis to the lung (Figure 8F). Collectively, these results indicate that ATM could 
possess dual functions in breast cancer tumor progression. In primary tumor sites, it 
serves as a tumor suppressor to inhibit the growth of cancer cells. On the other hand, 
based on our findings, ATM can also promote pro-metastatic processes such as cell 
migration and lung colonization.  
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Chapter 4 Discussion 
     In conclusion, in this study we have identified a tumor promoting activity for ATM. 
Little is known about cellular pathways regulated specifically by activated ATM via 
oxidation. Our results reveal a unique ATM signaling pathway that is activated 
independently of DSBs by endogenous oxidative stress to regulate the transcription of 
pro-metastatic genes including IL-8 (Figure 8G). Previous studies have demonstrated 
that ATM plays a role in senescence-associated secretory phenotype (SASP) in senescent 
cells (Coppe et al., 2010; Coppe et al., 2008). However, SASP is dependent on ATM, 
NBS1, and CHK2 in the presence of DNA damage. Our findings suggest that ATM and 
p53 promotes IL-8 expression independently of DNA damage. We propose that ATM 
through p53 can elicit an autocrine signaling pathway through the transcriptional 
regulation of pro-metastatic genes, including IL-8, to promote tumorigenesis. These 
processes are operational in cancer cells and can contribute to tumor progression. In line 
with this, a recent study has shown that ATM is required for the formation of acute 
myeloid leukemia as ATM is critical for maintaining the differentiation blockade and 
thereby promotes the growth of MLL-AF9 leukemic cells (Santos et al., 2014b).  
 
     Our study emphasizes that ATM can regulate the transcription of a set of genes 
involved in tumor progression. Gene ontology analysis revealed that the wound-healing 
pathway is co-regulated by ATM and p53. From this analysis, we identified several 
genes, including IL-8, C3, CXCL11, SAA2, and MMP1, that are involved in 
tumorigenesis. We identified IL-8 as an ATM target, and provided a link between 
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oxidative stress-activated ATM and tumor progression pathways in cancer cells. In 
addition, our results provide additional insights into other disease pathways involving 
ATM including angiogenesis, a pathway that has been shown to depend on oxidative 
stress and on IL-8 (Koch et al., 1992; Okuno et al., 2012). Inhibitors of the IL-8 pathway 
are actively being studied, developed and assessed in clinical trials for diseases including 
cancers and inflammation (Singh et al., 2013; Waugh and Wilson, 2008). Our current 
study suggests that ATM inhibitor could be utilized not only a radio-sensitizer but also a 
suppressor to inhibit tumor progression by abrogating IL-8 dependent cellular responses 
that includes cell migration and invasion as well as angiogenesis.  
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Figure 1. DSB-inducing agents have little effects on cell migration in MDA-MB-231 
cells. (A) Wound-healing assays of MDA-MB-231 cells untreated (Unt) or treated with 
doxorubicin (Dox, 100 nM), phleomycin (Phleo, 90 μg/ml), etoposide (Et, 40 µM) or 
ionizing radiation (IR, 20Gy). Drug treatments were for 48 hr.  IR treatment was 
performed at time 0. All samples were analyzed post-48 h from wound induction. Images 
were acquired at 0 and 48 h. Representative images from 3 independent experiments are 
shown. (B) Verification of DNA damage induction and quantification of wound healing 
from (A). γH2AX is a DNA damage marker and H2AX is a loading control. (C) Cell 
cycle analysis of cells treated in panel A by flow cytometry. (D) Proliferation of cells 
treated as in (A). After 48 h, cells were trypsinized, counted and normalized to untreated 
cells at 0 h. 
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Figure 2. ATM promotes cell migration in MDA-MB-231 cells. (A) ATM promotes cell 
migration in the absence of induced DSBs. Wound-healing assays were performed in 
siRNA-treated MDA-MB-231 human breast cancer cells with siNon-coding (siNC) or 
siATM siRNAs. (B) Verification of DNA damage induction and quantification of wound 
healing from (A). Top: Western blot analysis of samples from (A) with the ATM markers 
KAP1-pS824 and p53-pS15. Unmodified proteins are loading controls and ATM controls 
siRNA depletion. Bottom: Quantification of wound healing experiments from (A). (C) 
ATM depletion impairs cell migration and invasion, but not proliferation. Left panel: 
siNC or siATM cells were analyzed with xCELLigence Real-time cell analyzer (RTCA) 
to measure proliferation, migration and invasion in parallel and real-time. Experiments 
performed as detailed in Materials and methods. Right panel: ATM depletion 96 h post-
transfection. (mean ± s.e.m., n=3) 
 
 24 
 
Figure 3. ATM promotes cell migration and invasion independently of DSB signaling in 
MDA-MB-231 cells. (A) DSB signaling is not involved in cell migration. (B-C) 
Quantification of wound healing (B) and siRNA depletions (C) in (A). (D) Reactive 
oxygen species (ROS) inhibitor N-acetylcysteine (NAC) reduces cell migration. (E) NAC 
treatment reduces endogenous ROS. (F) Live-imaging analysis of cells treated with 10 
mM NAC or left untreated. Colored dots and lines represent individual cell paths. Scale 
bar, 37.5 µm. (G) Quantification of individual cell speed (µm/min) and cell path (µm) 
from (F). Error bars = SD. *** p-value <0.0001, unpaired two-tailed t-test. 
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Figure 4. ATM-p53 axis of the DNA damage response promotes cell migration and 
invasion in MDA-MB-231 cells. (A) ATM or p53 depletion, as well as co-depletion, 
impairs cell motility similarly. (B) siRNA depletions and quantification of wound healing 
for (A). (C) Real-time analysis of cell dynamics in siATM, sip53 and co-depleted cells. 
Right: ATM and p53 levels in cell samples. (D) Live cell imaging of cell migration 
defects in ATM and p53 depleted MDA-MB-231 cells. Scale bar, 20 µm. (E) 
Quantification of individual cell speed (µm/min) and cell path (µm) from (D). Error bars 
= SD. *** p-value <0.0001, unpaired two-tailed t-test. 
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Figure 5. Depletion of ATM or p53 reduces cellular motility in BT-549 human breast 
cancer cells. (A) ATM depletion impairs cell migration. Cells transfected with indicated 
siRNA were analyzed by wound-healing assays to determine cell motility. Right: 
Quantification of wound healing and ATM siRNA knockdown efficiency. (B) Reduction 
of ATM and/or p53 reduces cell migration. Cells were treated and analyzed with the 
indicated siRNAs as Figure 3A. Quantification of wound healing and depletion analysis 
is in right. 
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Figure 6. ATM-p53 regulates cytokine interleukin-8. (A) Differential transcriptome 
expression analysis in siATM- and sip53- depleted cells identifies reduced IL-8 
expression in both samples. Upper: Venn diagram of differentially expressed genes in 
sip53, siATM or both. Numbers indicate genes differentially expressed 1.5-fold or greater 
compared to siNC. Heatmap represents the 38 genes co-regulated similarly in siATM and 
sip53 cells. Expression data was normalized to control siNC cells. Cut-off = 1.5-fold 
normalized to siNC control cells. (B-C) qRT-PCR analysis of IL-8 mRNA levels in 
MDA-MB-231 (B) and BT-549 (C) siATM or sip53 depleted cells. (D) IL-8 promoter 
activity by luciferase reporter assay in siATM and sip53 cells. (E) NF-κB depletion 
impairs IL-8 expression. (F) ATM or p53 depletion abrogates NF-κB p65 nuclear 
localization. Cells treated with indicated siRNA were harvested to obtain cytoplasmic 
extract (CE) and nuclear extract (NE) to analyze NF-κB p65 localization. (G) ATM or 
p53 deletion impairs NF-κB p65 binding to IL-8 promoter using ChIP analysis. Actin 
promoter serves as a negative control. 
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Figure 7. ATM promotes pro-metastatic IL-8-dependent cellular processes. (A) IL-8 
depletion reduces cell migration and invasion. Error bars = SEM. * p-value <0.05, *** p-
value <0.001, unpaired two-tailed t-test. (B) IL-8 qRT-PCR analysis from samples in (A). 
(C) ROS inhibitor NAC reduces IL-8 expression. (D) H2O2-induced oxidative stress 
increases IL-8 expression. (E) H2O2-induced IL-8 expression is dependent on ATM. Cells 
treated with indicated siRNAs were incubated with 0.025 mM H2O2 or mock treated and 
analyzed by qPCR. (F-G) IL-8 addition restores impaired migration and invasion for 
ATM-depleted (F) or p53-depleted (G) cells. Experiments performed as in Figure 2C 
with or without recombinant IL-8. For all graphs, mean ± s.e.m., n=3. 
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Figure 8. ATM promotes tumor formation in vivo. (A) ATM is not required for colony 
growth in soft agar. Representative images of shNC and shATM are shown. (B) 
Quantification of soft agar assays. Colonies were counted from 10 fields of view. 
Differences between shNC and shATM are not significantly different (NS) by unpaired 
two-tailed t-test. (C) MDA-MB-231 shATM cells increase cancer cell proliferation 
compared to shNC cells by measuring orthotopic tumor growth. (D) ATM-depletion 
reduces lung tumor formation. Representative India ink stained lungs at necropsy from 
mice (N=12 for each group) following tail-vein injection xenografting of shNC or 
shATM MDA-MB-231 cells. Lung tumors indicated by arrows and dotted lines. (E) 
Quantification of average lung metastasis per mouse for shNC (N=12) and shATM 
(N=12) in D, p-value <0.0007 (unpaired two-tailed t-test). (F) Kaplan-Meier plot of 
probability of lung metastasis free survival in 560 breast cancer patients based on IL8 
expression levels. (G) Summary of ATM pathway in tumor progression. 
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